Xiaoting Wei

Years Active: 2022-2022
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Lili Mao, Meiyu Fang, Yu Chen, Xiaoting Wei, Jun Cao, Jing Lin, Peng Zhang, Ling Chen, Xiao Cao, Yujun Chen, Jun Guo, Lu Si
Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (21) (2022)
Xiaoting Wei, Di Wu, Yu Chen, Hang Li, Rui Zhang, Hong Yao, Zhihong Chi, Chuanliang Cui, Xue Bai, Lili Mao, Zhonghui Qi, Ke Li, Shijie Lan, Lizhu Chen, Rui Guo, Xinyu Yao, Bin Lian, Yan Kong, Jie Dai, Bixia Tang, Xuan Wang, Jun Guo, Lu Si
Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study. The British journal of dermatology 186 (6) (2022)
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Henry T Quach, Christopher G Cann, Michael Z Zhang, Lalit Pallan, Catriona Harvey, Michelle S Kim, Gyulnara Kasumova, Tatyana Sharova, Justine V Cohen, Donald P Lawrence, Christine Freedman, Riley M Fadden, Krista M Rubin, Dennie T Frederick, Keith T Flaherty, Georgina V Long, Alexander M Menzies, Ryan J Sullivan, Genevieve M Boland, Douglas B Johnson, Jun Guo
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. The British journal of dermatology 187 (3) (2022)

Xiaoting Wei.css-eqlu8i{font-size:small;padding-left:4px;}